Evidence map›Paper›PMID 35228335›Full record

ArticleNeurology2022

Race-Ethnic Disparities in Rates of Declination of Thrombolysis for Stroke.

Scott J Mendelson, Shuaiqi Zhang, Roland Matsouaka, Ying Xian, Shreyansh Shah, Barbara L Lytle, Nicole Solomon, Lee H Schwamm, Eric E Smith, Jeffrey L Saver and 3 more

Open access · greenAbstract read
In one paragraph

Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Estimating implicit and explicit racial and ethnic bias among community pharmacists in Canada.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  8. Article
  9. Racial and Ethnic Disparities in Stroke Reperfusion Therapy in the USA.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Scott J MendelsonFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.ORCID 0000-0002-3512-4332
Shuaiqi ZhangFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.ORCID 0000-0001-9184-4652
Roland MatsouakaFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.
Ying XianFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.
Shreyansh ShahFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.
Barbara L LytleFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.
Nicole SolomonFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.ORCID 0000-0002-5643-9958
Lee H SchwammFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.ORCID 0000-0003-0592-9145
Eric E SmithFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.ORCID 0000-0003-3956-1668
Jeffrey L SaverFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.ORCID 0000-0001-9141-2251
Gregg FonarowFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.
Jane HollFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.
Shyam PrabhakaranFrom the Department of Neurology (S.J.M., J.H., S.P.), Biological Sciences Division, University of Chicago, IL; Duke Clinical Research Institute (S.Z., R.M., Y.X., S.S., B.L.L., N.S.), Durham, NC; Department of Neurology and Comprehensive Stroke Center (L.H.S.), Massachusetts General Hospital and Harvard Medical School, Boston; Neurology (E.E.S.), Department of Clinical Neurosciences, University of Calgary, Alberta, Canada; Department of Neurology and Comprehensive Stroke Center (J.L.S.), David Geffen School of Medicine, University of California, Los Angeles; and Division of Cardiology (G.F.), Ronald Reagan-UCLA Medical Center, Los Angeles, CA.ORCID 0000-0003-3018-144X
Clinical Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesPrior regional or single-center studies have noted that 4% to 7% of eligible patients with acute ischemic stroke (AIS) decline IV tissue plasminogen activator (tPA). We sought to determine the prevalence of tPA declination in a nationwide registry of patients with AIS and to investigate differences in declination by race/ethnicity.

methodsWe used the Get With The Guidelines-Stroke registry to identify patients with AIS eligible for tPA and admitted to participating hospitals between January 1, 2016, and March 28, 2019. We compared patient demographics and admitting hospital characteristics between tPA-eligible patients who received and those who declined tPA. Using multivariable logistic regression, we determined patient and hospital factors associated with tPA declination.

resultsAmong 177,115 tPA-eligible patients with AIS at 1,976 sites, 6,545 patients (3.7%) had tPA declination as the sole documented reason for not receiving tPA. Patients declining treatment were slightly older, were more likely to be female, arrived more often at off-hours and earlier after symptom onset, and were more likely to present to Primary Stroke Centers. Compared with non-Hispanic White, non-Hispanic Black race/ethnicity was independently associated with increased (adjusted odds ratio [aOR] 1.21, 95% CI 1.11-1.31), Asian race/ethnicity with decreased (aOR 0.72, 95% CI 0.58-0.88), and Hispanic ethnicity (any race) with similar odds of tPA declination (OR 0.98, 95% CI 0.86-1.13) in multivariable analysis. DISCUSSION: Although the overall prevalence of tPA declination is low, eligible non-Hispanic Black patients are more likely and Asian patients less likely to decline tPA than non-Hispanic White patients. Reducing rates of tPA declinations among non-Hispanic Black patients may be an opportunity to address disparities in stroke care.

Indexed as

Brain IschemiaIschemic StrokeStrokeEthnicityFemaleFibrinolytic AgentsHumansMaleRetrospective StudiesThrombolytic TherapyTissue Plasminogen ActivatorFibrinolytic AgentsTissue Plasminogen Activator

Identifiers

PMID35228335
PMCPMC9052571
OpenAlexW4214528310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.